Haematological changes in the blood of Clarias gariepinus fed Chrysophyllum albidum seedmeal replacing maize

This study was conducted to investigate growth response of C. gariepinus fed diets containing C. albidum seed-meal replacing Five isonitrogenous diets containing maize which was replaced by C. albidum at a rate of 0,25, 50, 75 and 100% were made. Without C. albidum seed-meal served as the control, experimental diets were assigned randomly to the tanks and each group was fed 5% body weight in equal proportion per day. The fish fed diet 1 had the highest PCV while the fish fed diet 3 had the PCV. There was significant difference (p0.05) in the PCV of the fish fed diet 2, diet 3, diet 4, diet 5. A similar trend as observed for PCV was also Hb, RBC, MCV, MCH and MCHC. There was no significant difference (p>0.05) in the WBC of the blood of the fish fed various treatments so also were neutrophyls and lymphocytes

Effect of Fermented Lagenaria (Adenopus breviflorus) Fruit Extract on the Heamatological and Serum Biochemical Indices of Broiler Chickens

The experiment involved 126 day old broiler chicks (Arbor acre plus) which lasted for six weeks after two weeks of acclimatization. The project was carried out in a completely randomized block design to evaluate the haematological and serum biochemical parameters of broilers served fermented lagenaria fruit extract (FLFE) at three days interval. The birds were weighed and randomly distributed into six dietary treatment group. Birds in treatment A (control) were given vaccine and drugs only, birds in treatment B were given vaccine only, birds in treatment C were given drugs only, but birds in treatments D, E and F were served (100, 200 and 300)ml of FLFE in 250ml of water, respectively. Each treatment was replicated three times with seven birds per replicate. The birds were maintained on starter and finisher marsh for starter and finisher phase, respectively. Feeds and water were served ad libitum. Data collected were subjected to Analysis of Variance (ANOVA) and comparisons were made using Duncan’s Multiple Range Test and significance was accepted at (P<0.05). The parameters tested were packed cell volume (PCV), haemoglobin (Hb), red blood cell (RBC), white blood cell (WBC), platelet (P), mean cell volume (MCV), mean cell haemoglobin (MCH), mean cell haemoglobin concentration(MCHC), lymphocyte (LYM), heterocytes (HET), monocytes (Mn), eosinophils for haematological indices and total serum protein (TSP), albumin(Al), globumin (Gb), creatinine (Cr), alanine amino transminase (ALT), aspatate amino transminase (AST), alkaline phosphate (ALP), blood urea nitrogen (BUN) and cholesterol (CH) for serum biochemistry. The results showed significant (P<0.05) effects of the parameters studied across the treatment groups. The PCV was highest (40.00%) on the birds placed in control, and least on the birds served 100-300ml FLFE (29.50-33.00%). Similar scenario was observed for the birds in control for the Hb (13.20%) compared to those served 100-300ml FLFE (9.40-10.70%). The birds in treatments C (drugs only), D (100ml FLFE) and those in F (300ml FLFE) had the highest concentration of white blood cells which were 1.92, 2.12 and 1.87x104/ml, respectively. The birds served 100-300ml FLFE had reduced concentration of Hb of 21.25% compared to control, and they had elevated concentration of WBC of 25.82% compared to control. The birds placed on vaccines only and drugs only had elevated WBC of 26.00 and 34.50%, respectively compared to control. The FLFE of 100-200ml had elevated platelet (353.00-314.50x103/ml) with reference to control. The FLFE had no significant (P<0.05) effect on TSP, GB, AL, ALP and BUN. However, concentration of CH increased with increased concentration of FLFE as the bird offered 100ml had CH of 42.50mg/dl, compared to those on 200ml and 300ml whose value were 68.50 and 89.00mg/dl, respectively. Broiler chicken can tolerate 100-300ml FLFE for improved blood formation. Keywords: Lagenaria, Hematology, Serum biochemistry, Broiler, Vaccin

Evaluation of varying levels of Carica papaya leaf meal on growth, carcass, hematological parameters and its use as anticoccidial for broiler chicken

Medicinal plants have been traditionally used for treatments of various diseases in many countries. Carica papaya is one of potential feed supplements which have recently been reported as having a wide range of beneficial effects on production performance. A seven weeks trial was conducted to investigate the effect of graded levels of C. papaya leaf meal on broiler growth performance, carcass characteristics, hematological parameters and its anticoccidial properties. A total of one hundred and fifty day-old Marshal broiler chicks were randomly allotted to five dietary treatments with 30 birds per treatment, replicated thrice in a completely randomized design. The treatments were; diet with coccidiostat as a positive control (T1), diet without C. papaya leaf meal nor coccidiostat (T2), diet with 200 g of C. papaya leaf meal/100kg of feed (T3), diet with 400 g C. papaya leaf meal/100kg of feed (T4), and diet with 600 g of C. papaya leaf meal/100kg of feed (T5). The phytochemical component of the C. papaya leaf meal varied from positive to strongly positive. Significant differences (P<0.05) were observed in the final weight, feed intake and the mortality percentage. The best liveability and final weight gain were obtained from the birds fed diets with 400 g of C. papaya leaf meal while non significance differences were observed on the carcass characteristics except on the live weight. The blood profiles were within the normal levels. It can be concluded that C. papaya leaf meal can be used at the rate of 400 g/100kg of feed for broiler chicken without any deleterious effect on the performance and carcass characteristics. Keywords: Carica papaya, performance, coccidiostat, phytochemical, carcass, hematological

Anemia prevalence in women of reproductive age in low- and middle-income countries between 2000 and 2018

Anemia is a globally widespread condition in women and is associated with reduced economic productivity and increased mortality worldwide. Here we map annual 2000–2018 geospatial estimates of anemia prevalence in women of reproductive age (15–49 years) across 82 low- and middle-income countries (LMICs), stratify anemia by severity and aggregate results to policy-relevant administrative and national levels. Additionally, we provide subnational disparity analyses to provide a comprehensive overview of anemia prevalence inequalities within these countries and predict progress toward the World Health Organization’s Global Nutrition Target (WHO GNT) to reduce anemia by half by 2030. Our results demonstrate widespread moderate improvements in overall anemia prevalence but identify only three LMICs with a high probability of achieving the WHO GNT by 2030 at a national scale, and no LMIC is expected to achieve the target in all their subnational administrative units. Our maps show where large within-country disparities occur, as well as areas likely to fall short of the WHO GNT, offering precision public health tools so that adequate resource allocation and subsequent interventions can be targeted to the most vulnerable populations.Peer reviewe

Mapping geographical inequalities in childhood diarrhoeal morbidity and mortality in low-income and middle-income countries, 2000–17 : analysis for the Global Burden of Disease Study 2017

Background Across low-income and middle-income countries (LMICs), one in ten deaths in children younger than 5 years is attributable to diarrhoea. The substantial between-country variation in both diarrhoea incidence and mortality is attributable to interventions that protect children, prevent infection, and treat disease. Identifying subnational regions with the highest burden and mapping associated risk factors can aid in reducing preventable childhood diarrhoea. Methods We used Bayesian model-based geostatistics and a geolocated dataset comprising 15 072 746 children younger than 5 years from 466 surveys in 94 LMICs, in combination with findings of the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017, to estimate posterior distributions of diarrhoea prevalence, incidence, and mortality from 2000 to 2017. From these data, we estimated the burden of diarrhoea at varying subnational levels (termed units) by spatially aggregating draws, and we investigated the drivers of subnational patterns by creating aggregated risk factor estimates. Findings The greatest declines in diarrhoeal mortality were seen in south and southeast Asia and South America, where 54·0% (95% uncertainty interval [UI] 38·1–65·8), 17·4% (7·7–28·4), and 59·5% (34·2–86·9) of units, respectively, recorded decreases in deaths from diarrhoea greater than 10%. Although children in much of Africa remain at high risk of death due to diarrhoea, regions with the most deaths were outside Africa, with the highest mortality units located in Pakistan. Indonesia showed the greatest within-country geographical inequality; some regions had mortality rates nearly four times the average country rate. Reductions in mortality were correlated to improvements in water, sanitation, and hygiene (WASH) or reductions in child growth failure (CGF). Similarly, most high-risk areas had poor WASH, high CGF, or low oral rehydration therapy coverage. Interpretation By co-analysing geospatial trends in diarrhoeal burden and its key risk factors, we could assess candidate drivers of subnational death reduction. Further, by doing a counterfactual analysis of the remaining disease burden using key risk factors, we identified potential intervention strategies for vulnerable populations. In view of the demands for limited resources in LMICs, accurately quantifying the burden of diarrhoea and its drivers is important for precision public health

Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021

Background: Disorders affecting the nervous system are diverse and include neurodevelopmental disorders, late-life neurodegeneration, and newly emergent conditions, such as cognitive impairment following COVID-19. Previous publications from the Global Burden of Disease, Injuries, and Risk Factor Study estimated the burden of 15 neurological conditions in 2015 and 2016, but these analyses did not include neurodevelopmental disorders, as defined by the International Classification of Diseases (ICD)-11, or a subset of cases of congenital, neonatal, and infectious conditions that cause neurological damage. Here, we estimate nervous system health loss caused by 37 unique conditions and their associated risk factors globally, regionally, and nationally from 1990 to 2021. Methods: We estimated mortality, prevalence, years lived with disability (YLDs), years of life lost (YLLs), and disability-adjusted life-years (DALYs), with corresponding 95% uncertainty intervals (UIs), by age and sex in 204 countries and territories, from 1990 to 2021. We included morbidity and deaths due to neurological conditions, for which health loss is directly due to damage to the CNS or peripheral nervous system. We also isolated neurological health loss from conditions for which nervous system morbidity is a consequence, but not the primary feature, including a subset of congenital conditions (ie, chromosomal anomalies and congenital birth defects), neonatal conditions (ie, jaundice, preterm birth, and sepsis), infectious diseases (ie, COVID-19, cystic echinococcosis, malaria, syphilis, and Zika virus disease), and diabetic neuropathy. By conducting a sequela-level analysis of the health outcomes for these conditions, only cases where nervous system damage occurred were included, and YLDs were recalculated to isolate the non-fatal burden directly attributable to nervous system health loss. A comorbidity correction was used to calculate total prevalence of all conditions that affect the nervous system combined. Findings: Globally, the 37 conditions affecting the nervous system were collectively ranked as the leading group cause of DALYs in 2021 (443 million, 95% UI 378–521), affecting 3·40 billion (3·20–3·62) individuals (43·1%, 40·5–45·9 of the global population); global DALY counts attributed to these conditions increased by 18·2% (8·7–26·7) between 1990 and 2021. Age-standardised rates of deaths per 100 000 people attributed to these conditions decreased from 1990 to 2021 by 33·6% (27·6–38·8), and age-standardised rates of DALYs attributed to these conditions decreased by 27·0% (21·5–32·4). Age-standardised prevalence was almost stable, with a change of 1·5% (0·7–2·4). The ten conditions with the highest age-standardised DALYs in 2021 were stroke, neonatal encephalopathy, migraine, Alzheimer's disease and other dementias, diabetic neuropathy, meningitis, epilepsy, neurological complications due to preterm birth, autism spectrum disorder, and nervous system cancer. Interpretation: As the leading cause of overall disease burden in the world, with increasing global DALY counts, effective prevention, treatment, and rehabilitation strategies for disorders affecting the nervous system are needed. Funding: Bill & Melinda Gates Foundation

Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950–2021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the Global Burden of Disease Study 2021

Background: Estimates of demographic metrics are crucial to assess levels and trends of population health outcomes. The profound impact of the COVID-19 pandemic on populations worldwide has underscored the need for timely estimates to understand this unprecedented event within the context of long-term population health trends. The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021 provides new demographic estimates for 204 countries and territories and 811 additional subnational locations from 1950 to 2021, with a particular emphasis on changes in mortality and life expectancy that occurred during the 2020–21 COVID-19 pandemic period. Methods: 22 223 data sources from vital registration, sample registration, surveys, censuses, and other sources were used to estimate mortality, with a subset of these sources used exclusively to estimate excess mortality due to the COVID-19 pandemic. 2026 data sources were used for population estimation. Additional sources were used to estimate migration; the effects of the HIV epidemic; and demographic discontinuities due to conflicts, famines, natural disasters, and pandemics, which are used as inputs for estimating mortality and population. Spatiotemporal Gaussian process regression (ST-GPR) was used to generate under-5 mortality rates, which synthesised 30 763 location-years of vital registration and sample registration data, 1365 surveys and censuses, and 80 other sources. ST-GPR was also used to estimate adult mortality (between ages 15 and 59 years) based on information from 31 642 location-years of vital registration and sample registration data, 355 surveys and censuses, and 24 other sources. Estimates of child and adult mortality rates were then used to generate life tables with a relational model life table system. For countries with large HIV epidemics, life tables were adjusted using independent estimates of HIV-specific mortality generated via an epidemiological analysis of HIV prevalence surveys, antenatal clinic serosurveillance, and other data sources. Excess mortality due to the COVID-19 pandemic in 2020 and 2021 was determined by subtracting observed all-cause mortality (adjusted for late registration and mortality anomalies) from the mortality expected in the absence of the pandemic. Expected mortality was calculated based on historical trends using an ensemble of models. In location-years where all-cause mortality data were unavailable, we estimated excess mortality rates using a regression model with covariates pertaining to the pandemic. Population size was computed using a Bayesian hierarchical cohort component model. Life expectancy was calculated using age-specific mortality rates and standard demographic methods. Uncertainty intervals (UIs) were calculated for every metric using the 25th and 975th ordered values from a 1000-draw posterior distribution. Findings: Global all-cause mortality followed two distinct patterns over the study period: age-standardised mortality rates declined between 1950 and 2019 (a 62·8% [95% UI 60·5–65·1] decline), and increased during the COVID-19 pandemic period (2020–21; 5·1% [0·9–9·6] increase). In contrast with the overall reverse in mortality trends during the pandemic period, child mortality continued to decline, with 4·66 million (3·98–5·50) global deaths in children younger than 5 years in 2021 compared with 5·21 million (4·50–6·01) in 2019. An estimated 131 million (126–137) people died globally from all causes in 2020 and 2021 combined, of which 15·9 million (14·7–17·2) were due to the COVID-19 pandemic (measured by excess mortality, which includes deaths directly due to SARS-CoV-2 infection and those indirectly due to other social, economic, or behavioural changes associated with the pandemic). Excess mortality rates exceeded 150 deaths per 100 000 population during at least one year of the pandemic in 80 countries and territories, whereas 20 nations had a negative excess mortality rate in 2020 or 2021, indicating that all-cause mortality in these countries was lower during the pandemic than expected based on historical trends. Between 1950 and 2021, global life expectancy at birth increased by 22·7 years (20·8–24·8), from 49·0 years (46·7–51·3) to 71·7 years (70·9–72·5). Global life expectancy at birth declined by 1·6 years (1·0–2·2) between 2019 and 2021, reversing historical trends. An increase in life expectancy was only observed in 32 (15·7%) of 204 countries and territories between 2019 and 2021. The global population reached 7·89 billion (7·67–8·13) people in 2021, by which time 56 of 204 countries and territories had peaked and subsequently populations have declined. The largest proportion of population growth between 2020 and 2021 was in sub-Saharan Africa (39·5% [28·4–52·7]) and south Asia (26·3% [9·0–44·7]). From 2000 to 2021, the ratio of the population aged 65 years and older to the population aged younger than 15 years increased in 188 (92·2%) of 204 nations. Interpretation: Global adult mortality rates markedly increased during the COVID-19 pandemic in 2020 and 2021, reversing past decreasing trends, while child mortality rates continued to decline, albeit more slowly than in earlier years. Although COVID-19 had a substantial impact on many demographic indicators during the first 2 years of the pandemic, overall global health progress over the 72 years evaluated has been profound, with considerable improvements in mortality and life expectancy. Additionally, we observed a deceleration of global population growth since 2017, despite steady or increasing growth in lower-income countries, combined with a continued global shift of population age structures towards older ages. These demographic changes will likely present future challenges to health systems, economies, and societies. The comprehensive demographic estimates reported here will enable researchers, policy makers, health practitioners, and other key stakeholders to better understand and address the profound changes that have occurred in the global health landscape following the first 2 years of the COVID-19 pandemic, and longer-term trends beyond the pandemic. Funding: Bill & Melinda Gates Foundation